期刊
JOURNAL OF CLINICAL PHARMACOLOGY
卷 40, 期 3, 页码 219-230出版社
WILEY
DOI: 10.1177/00912700022008883
关键词
-
资金
- NATIONAL INSTITUTE ON AGING [R01AG015982] Funding Source: NIH RePORTER
- NCRR NIH HHS [RR-00048] Funding Source: Medline
- NIA NIH HHS [R01 AG15982] Funding Source: Medline
- PHS HHS [K0700768] Funding Source: Medline
Pharmacokinetic studies of i.v. and oral racemic verapamil and C-14-erythromycin breath tests (ERBT) were performed in 84 healthy men (n = 42) and women (n = 42). Verapamil was measured by HPLC, concentration versus time data were analyzed by noncompartmental; models, protein binding was measured by equilibrium dialysis, and statistical analyses were performed by ANOVA. Clearance of i.v. and p.o. verapamil was 13.7 +/- 4.3 and 58.4 +/- 35 ml/min/kg (mean + SD) in women compared to 12.6 +/- 3.4 and 82.6 +/- 70 ml/min/kg in men (p = 0.076). Bioavailability was higher in women (0.25 +/- 0.09) compared to men 10.20 +/- 0.09, (p = 0.019) with a significant Gender x Formulation interaction (p = 0.04). ERBT were higher in women (p < 0.0001). Verapamil (i.v. and p.o.) decreased blood pressure in all subjects with greater heart rate increases after p.o. verapamil in women compared to men (p = 0.041). The findings suggest that sex-specific differences in drug metabolism may occur in both the gut and the liver and involve multiple metabolic pathways and that pharmacokinetic differences will alter pharmacodynamic responses. (C) 2000 the American College of Clinical Pharmacology.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据